Article Details
Retrieved on: 2024-03-08 19:42:00
Tags for this article:
Click the tags to see associated articles and topics
Excerpt
The analyst underwrites that 15-20% of patients are not eligible for Sarepta/Pfizer Inc (NYSE:PFE) due to neutralizing antibodies. The analyst notes a ...
Article found on: markets.businessinsider.com
This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here